Any current/future new fundraising through debt or equity?

No major new CAPEX programs planned currently; only maintenance CAPEX (about 4–5% of gross block) ongoing. Debt increased in the last financial year due to expansion projects; no further significant increase in net debt is expected going forward. The company prefers to use debt as a financial tool rather than equity because cost of debt is lower than equity. There was a suggestion to deleverage and focus on paying down debt before incurring growth CAPEX, but the company intends to keep debt on books for leverage and strategic reasons. No explicit mention of impending new fundraising th

Any current/future capex/capital investment/strategic investment?

Most major CAPEX projects outside India are completed, including the new French facility (~$50 million), Swiss ADC expansion, and Indian lab and infrastructure upgrades. Future CAPEX will mainly be maintenance-related, around 4-5% of the gross block, estimated at CHF 35-40 million annually for FY '24 and FY '25. A significant upcoming expense is the digital transformation project implementing SAP across Carbogen Amcis, aimed at streamlining operations and delivering cost benefits long-term. The Hunzenschwil facility expansion project is currently on hold, with the land procured and preliminary

Future growth expectations in sales/revenue/volumes?

The company anticipates a top-line growth of 12% to 15% CAGR over the next 5 years. Management is confident of sustainable growth, having addressed past cyclical challenges, improving manufacturing quality, manpower, and processes. The Bavla facility, despite EDQM inspection delays, is expected to perform strongly with revenues higher than the last financial year and no seasonality impact. Investment in new capacities like the cells facility is already showing promising progress with revenue reaching 50% of the second-year target shortly after launch. The company foresees double-digit

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates top-line growth of 12% to 15% CAGR over the next 5 years (Page 11). Targeting EBITDA margin improvement back to 25%-26% levels seen in 2019-2020 (Page 10). Expecting at least 20% plus EBITDA growth in FY '24 compared to FY '23, supporting significant PAT improvement (Page 9). Confident about consistent top-line and profitability growth, moving into positive profit territory in the current fiscal year (Page 9). Growth attributed to resolving past challenges (e.g., EDQM inspection delays) and ramp-up of the Bavla facility alongside strong overseas subsidiary performance (

Current/ Expected Orderbook/ Pending Orders?

Carbogen Amcis has a very strong order book as of FY '23. The company completed almost all one-off write-offs in FY '23. They are confident of achieving at least double-digit top-line growth in FY '24. EBITDA growth is expected to be aggressive, targeting 20%+ growth compared to FY '23. This strong order book and growth outlook position the company on a significantly positive trajectory for profitability (PAT). The management is positive about consistent growth and a strong pipeline supporting future orders, despite historical cyclicality and challenges.

IN US

Sale is live|00:00:00left today

Dishman Carbogen Amcis LtdQ1 FY24Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹191P/E: 23.1Market Cap: ₹3.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 3

→The company anticipates a top-line growth of 12% to 15% CAGR over the next 5 years.
→Management is confident of sustainable growth, having addressed past cyclical challenges, improving manufacturing quality, manpower, and processes.
→The Bavla facility, despite EDQM inspection delays, is expected to perform strongly with revenues higher than the last financial year and no seasonality impact.
→Investment in new capacities like the cells facility is already showing promising progress with revenue reaching 50% of the second-year target shortly after launch.
→The company foresees double-digit growth in top line and over 20% growth in EBITDA, aiming to return to pre-2019 profitability levels.
→Long-term growth confidence is based on the industry’s significant gap and contract research and manufacturing demand, expected to last at least two decades.

Margin guidance

Category 1

→The company anticipates top-line growth of 12% to 15% CAGR over the next 5 years (Page 11).
→Targeting EBITDA margin improvement back to 25%-26% levels seen in 2019-2020 (Page 10).
→Expecting at least 20% plus EBITDA growth in FY '24 compared to FY '23, supporting significant PAT improvement (Page 9).
→Confident about consistent top-line and profitability growth, moving into positive profit territory in the current fiscal year (Page 9).
→Growth attributed to resolving past challenges (e.g., EDQM inspection delays) and ramp-up of the Bavla facility alongside strong overseas subsidiary performance (Page 10).
→Projected bright future over next two decades due to market gaps and strategic investments (Page 22).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No major new CAPEX programs planned currently; only maintenance CAPEX (about 4–5% of gross block) ongoing.
→Debt increased in the last financial year due to expansion projects; no further significant increase in net debt is expected going forward.
→The company prefers to use debt as a financial tool rather than equity because cost of debt is lower than equity.
→There was a suggestion to deleverage and focus on paying down debt before incurring growth CAPEX, but the company intends to keep debt on books for leverage and strategic reasons.
→No explicit mention of impending new fundraising through debt or equity in the near term.
→Related party loan repayment is planned to clear before fiscal year-end, reducing related-party exposures and potentially impacting debt profile.

Order book

Yes

→Carbogen Amcis has a very strong order book as of FY '23.
→The company completed almost all one-off write-offs in FY '23.
→They are confident of achieving at least double-digit top-line growth in FY '24.
→EBITDA growth is expected to be aggressive, targeting 20%+ growth compared to FY '23.
→This strong order book and growth outlook position the company on a significantly positive trajectory for profitability (PAT).
→The management is positive about consistent growth and a strong pipeline supporting future orders, despite historical cyclicality and challenges.

Capex plans

Yes

→Most major CAPEX projects outside India are completed, including the new French facility (~$50 million), Swiss ADC expansion, and Indian lab and infrastructure upgrades.
→Future CAPEX will mainly be maintenance-related, around 4-5% of the gross block, estimated at CHF 35-40 million annually for FY '24 and FY '25.
→A significant upcoming expense is the digital transformation project implementing SAP across Carbogen Amcis, aimed at streamlining operations and delivering cost benefits long-term.
→The Hunzenschwil facility expansion project is currently on hold, with the land procured and preliminary engineering completed; no additional debt is planned to finance this at present.
→Management views these investments as strategic, enabling long-term growth and enhanced manufacturing capabilities, particularly in formulations and injectable products.
→No immediate major new CAPEX beyond maintenance and digital transformation; growth CAPEX to be reconsidered upon reaching revenue milestones (~Rs. 3,200-3,500 crore).

How does Dishman Carbogen Amcis Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Dishman Carbogen Amcis Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings